- ►annals.org [PDF] J Desai, L Yassa, E Marqusee, S George, MC … - Annals of internal medicine, 2006 - Am Coll Physicians Background: Sunitinib malate is an oral tyrosine kinase inhibitor recently
approved for the treatment of gastrointestinal stromal tu- mors and renal cell
carcinoma. Because the ret proto-oncogene is also inhibited by this agent, ... Cited by 121 - Related articles - BL Direct - All 5 versions
- ►oxfordjournals.org BI Rini, I Tamaskar, P Shaheen, R Salas, J … - JNCI Journal of the National Cancer Institute, 2007 - jnci.oxfordjournals.org Sunitinib is an inhibitor of the vascular endothelial growth factor and
platelet-derived growth factor receptors, and it has antitumor activity in
metastatic renal cell carcinoma and gastrointestinal stromal tumors. To ... Cited by 125 - Related articles - BL Direct - All 6 versions
E Wong, LS Rosen, M Mulay, A VanVugt, M … - Thyroid, 2007 - liebertonline.com Objective: Sunitinib is a novel tyrosine kinase inhibitor with antitumor and
antiangiogenic effects. An observed higher than expected rate of hypothyroidism
in sunitinib-treated patients prompted assessment of the incidence of ... Cited by 29 - Related articles - BL Direct - All 4 versions
- ►endojournals.org D Mannavola, P Coco, G Vannucchi, R … - Journal of Clinical Endocrinology & Metabolism, 2007 - Endocrine Soc Context: Sunitinib (sunitinib malate; SU11248; Sutent; Pfizer Inc., New York,
NY) is a multitarget inhibitor of tyrosine kinases for the treatment of some
human cancers. A myxedematous coma in a patient treated with sunitinib for ... Cited by 30 - Related articles - BL Direct - All 6 versions
- ►nih.gov TF Chu, MA Rupnick, R Kerkela, SM … - The Lancet, 2007 - Elsevier Eight of 75 (11%) patients given repeating cycles of sunitinib in the phase I/II
trial had a cardiovascular event, with congestive heart failure recorded in six
of 75 (8%). Ten of 36 (28%) patients treated at the approved sunitinib dose ... Cited by 123 - Related articles - All 44 versions
P Schoeffski, P Wolter, U Himpe, SS Dychter … - ASCO Meeting Abstracts, 2006 - meeting.ascopubs.org Background: Sunitinib is a multi-target tyrosine kinase inhibitor with
anti-angiogenic and anti-proliferative activity mediated by signal blockade of
VEGFR1/2, KIT, PDGFR /ß, and FLT-3. Phase II/III trials have demonstrated ... Cited by 19 - Related articles - All 3 versions
- ►heinrich-corless.net [PDF] GD Demetri, AT van Oosterom, CR Garrett, ME … - The Lancet, 2006 - Elsevier 312 patients were randomised in a 2:1 ratio to receive sunitinib (n=207) or
placebo (n=105); the trial was unblinded early when a planned interim analysis
showed significantly longer time to tumour progression with sunitinib. ... Cited by 438 - Related articles - All 25 versions
- ►oxfordjournals.org I Tamaskar, R Bukowski, P Elson, AG … - Annals of Oncology, 2007 - Eur Soc Med Oncology Background: Sorafenib is an orally bioavailable vascular endothelial growth
factor receptor (VEGFR) inhibitor with antitumor activity in metastatic renal
cell carcinoma (RCC). Sunitinib, also a VEGFR inhibitor, induces ... Cited by 26 - Related articles - BL Direct - All 5 versions
JWB de Groot, BA Zonnenberg, JTM Plukker, … - Clinical Pharmacology & Therapeutics, 2005 - nature.com Interactions of imatinib with other drugs have been scarcely reported. We report
a previously unknown effect of imatinib on levothyroxine therapy. Eleven
patients (1 with gastrointestinal stromal tumor and 10 with medullary ... Cited by 23 - Related articles - All 4 versions
- ►ascopubs.org S Faivre, C Delbaldo, K Vera, C Robert, S … - Journal of Clinical Oncology, 2006 - jco.ascopubs.org Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
PURPOSE: To establish the safety, pharmacokinetics, and recommended dose of ... Cited by 374 - Related articles - All 9 versions
